Creative Medical Technology (CELZ)
Market Price (3/30/2026): $1.89 | Market Cap: $5.1 MilSector: Health Care | Industry: Biotechnology
Creative Medical Technology (CELZ)
Market Price (3/30/2026): $1.89Market Cap: $5.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -136% | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -124% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -102380% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -38% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Expensive valuation multiplesP/SPrice/Sales ratio is 881x |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -38%, Rev Chg QQuarterly Revenue Change % is 0.0% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -97607%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -97607% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -117% | ||
| High stock price volatilityVol 12M is 101% | ||
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.38 | ||
| Key risksCELZ key risks include [1] a heavy dependency on the success of its key clinical trials like ADAPT and CREATE-1, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -136% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -38% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -124% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -102380% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 881x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -45%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -38%, Rev Chg QQuarterly Revenue Change % is 0.0% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 58% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -97607%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -97607% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -117% |
| High stock price volatilityVol 12M is 101% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.38 |
| Key risksCELZ key risks include [1] a heavy dependency on the success of its key clinical trials like ADAPT and CREATE-1, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Creative Medical Technology (CELZ) stock has lost about 25% since 11/30/2025 because of the following key factors:
1. Persistent Financial Losses and Minimal Revenue Generation. Creative Medical Technology has continued to report significant financial losses, with an annual loss of -$5.5 million for fiscal year 2024 and -$6.0 million for the trailing 12 months ending September 30, 2025. The company's recorded annual revenue stands at a minimal $10,000.00. While analysts anticipate a breakeven by 2027, this long-term outlook for profitability, coupled with ongoing capital burn, likely weighed on investor sentiment within the specified period.
2. Negative Market Response to Positive Clinical Data. Despite announcing positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial for CELZ-201 (Olastrocel) on January 13, 2026, the company's stock experienced an 11.22% decline on the day of the announcement. This negative market reaction, which removed approximately $905,000 from the company's valuation, suggests that even favorable clinical milestones may not have met elevated investor expectations or were overshadowed by other concerns, leading to significant selling pressure.
Show more
1. Persistent Financial Losses and Minimal Revenue Generation. Creative Medical Technology has continued to report significant financial losses, with an annual loss of -$5.5 million for fiscal year 2024 and -$6.0 million for the trailing 12 months ending September 30, 2025. The company's recorded annual revenue stands at a minimal $10,000.00. While analysts anticipate a breakeven by 2027, this long-term outlook for profitability, coupled with ongoing capital burn, likely weighed on investor sentiment within the specified period.
2. Negative Market Response to Positive Clinical Data. Despite announcing positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial for CELZ-201 (Olastrocel) on January 13, 2026, the company's stock experienced an 11.22% decline on the day of the announcement. This negative market reaction, which removed approximately $905,000 from the company's valuation, suggests that even favorable clinical milestones may not have met elevated investor expectations or were overshadowed by other concerns, leading to significant selling pressure.
Show more
Stock Movement Drivers
Fundamental Drivers
The -26.8% change in CELZ stock from 11/30/2025 to 3/29/2026 was primarily driven by a -23.8% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.69 | 1.97 | -26.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 1,156.9 | 881.4 | -23.8% |
| Shares Outstanding (Mil) | 3 | 3 | -3.9% |
| Cumulative Contribution | -26.8% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CELZ | -26.8% | |
| Market (SPY) | -5.3% | 23.6% |
| Sector (XLV) | -8.7% | 18.8% |
Fundamental Drivers
The -38.1% change in CELZ stock from 8/31/2025 to 3/29/2026 was primarily driven by a -35.6% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.18 | 1.97 | -38.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 1,367.7 | 881.4 | -35.6% |
| Shares Outstanding (Mil) | 3 | 3 | -3.9% |
| Cumulative Contribution | -38.1% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CELZ | -38.1% | |
| Market (SPY) | 0.6% | 25.0% |
| Sector (XLV) | 5.2% | 13.0% |
Fundamental Drivers
The -60.4% change in CELZ stock from 2/28/2025 to 3/29/2026 was primarily driven by a -48.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.97 | 1.97 | -60.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -45.5% |
| P/S Multiple | 629.1 | 881.4 | 40.1% |
| Shares Outstanding (Mil) | 1 | 3 | -48.1% |
| Cumulative Contribution | -60.4% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CELZ | -60.4% | |
| Market (SPY) | 9.8% | 17.7% |
| Sector (XLV) | -2.1% | 10.5% |
Fundamental Drivers
The -65.4% change in CELZ stock from 2/28/2023 to 3/29/2026 was primarily driven by a -95.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.70 | 1.97 | -65.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -95.6% |
| P/S Multiple | 58.2 | 881.4 | 1414.0% |
| Shares Outstanding (Mil) | 1 | 3 | -47.6% |
| Cumulative Contribution | -65.4% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CELZ | -65.4% | |
| Market (SPY) | 69.4% | 12.9% |
| Sector (XLV) | 18.4% | 9.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CELZ Return | 31471% | -83% | 21% | -50% | -15% | 1% | 2729% |
| Peers Return | -23% | -19% | 67% | -5% | -1% | -21% | -22% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| CELZ Win Rate | 8% | 8% | 58% | 25% | 58% | 67% | |
| Peers Win Rate | 47% | 52% | 52% | 50% | 50% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CELZ Max Drawdown | 0% | -84% | -2% | -57% | -22% | -9% | |
| Peers Max Drawdown | -36% | -42% | -17% | -25% | -35% | -28% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ORGO, MDXG, SRPT, CRSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | CELZ | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -92.4% | -25.4% |
| % Gain to Breakeven | 1209.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -90.2% | -33.9% |
| % Gain to Breakeven | 924.4% | 51.3% |
| Time to Breakeven | 613 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.0% | -19.8% |
| % Gain to Breakeven | 5000.0% | 24.7% |
| Time to Breakeven | 70 days | 120 days |
Compare to VRTX, ORGO, MDXG, SRPT, CRSP
In The Past
Creative Medical Technology's stock fell -92.4% during the 2022 Inflation Shock from a high on 3/28/2022. A -92.4% loss requires a 1209.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Creative Medical Technology (CELZ)
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
AI Analysis | Feedback
Here are 1-3 brief analogies for Creative Medical Technology (CELZ):
- They're like a 'Moderna for regenerative medicine,' developing adult stem cell therapies for a wide range of conditions from stroke to infertility.
- Think of them as an 'Eli Lilly focused entirely on adult stem cell treatments,' building a pipeline of novel therapies for diverse ailments like chronic back pain and erectile dysfunction.
- They're like a 'Medtronic for cellular regeneration,' developing adult stem cell solutions for diverse conditions like stroke recovery and back pain.
AI Analysis | Feedback
```html- CaverStem: An adult stem cell treatment designed to treat erectile dysfunction.
- FemCelz: An adult stem cell treatment for the treatment of loss of genital sensitivity and dryness.
- StemSpine: An adult stem cell treatment aimed at addressing chronic lower back pain.
- ImmCelz: An adult stem cell treatment developed for the treatment of stroke patients.
- OvaStem: An adult stem cell treatment used for the treatment of female infertility.
AI Analysis | Feedback
Creative Medical Technology Holdings, Inc. (CELZ) sells primarily to other companies rather than directly to individuals. Its major customers are:
- Medical practices and clinics: These healthcare providers license or purchase Creative Medical Technology's stem cell treatment protocols and products (such as CaverStem, FemCelz, StemSpine, ImmCelz, and OvaStem) to administer to their own patients. These customers include urology clinics, pain management centers, fertility clinics, and other specialized medical facilities that offer regenerative medicine treatments.
Most of these medical practices and clinics are privately owned and operated, and therefore do not have public company symbols.
AI Analysis | Feedback
nullAI Analysis | Feedback
Timothy Warbington, Chief Executive Officer & Co-Founder
Timothy Warbington is an accomplished entrepreneur and healthcare executive, best known as the founder and CEO of Creative Medical Technology Holdings (NASDAQ: CELZ). He has over 12 years of experience in the healthcare industry and more than 25 years of executive-level management experience. Warbington earned a Bachelor's degree in Accounting from Arizona State University. For over two decades, he was a principal of a leading agriculture company. In 2006, he began investing in early-stage biotech companies, where his advisory roles contributed to increased valuations and successful exits. He founded Creative Medical in 2011 with the goal of revolutionizing regenerative medicine and successfully led the company to NASDAQ.
Donald Dickerson, Chief Financial Officer & Senior Vice-President
Donald Dickerson has served as Chief Financial Officer and Senior Vice-President of Creative Medical Technology Holdings since February 2016. He also served as a director and as Vice President and Chief Operating Officer of CMH (Creative Medical Health) since June 2014. Mr. Dickerson received his Masters of Business Administration in Finance from the University of Southern California in May 1992. He has extensive experience in management and accounting positions across technology, manufacturing, and health sciences companies.
Dr. Thomas Ichim, Chief Scientific Officer
Dr. Thomas Ichim was appointed Chief Scientific Officer in March 2017. He is a world-renowned scientist and a seasoned biotechnology entrepreneur who has founded or served in a leadership capacity with multiple biomedical companies, including Batu Biologics, ToleroTech Technology, Medistem Inc., Medvax Pharma Corp., bioRASI, and OncoMune LLC. Dr. Ichim is credited with pioneering new and innovative processes in the biomedical field and is an inventor with a significant portfolio of patents. He possesses extensive experience in stem cell therapy and cellular product development, including navigating FDA regulatory pathways. Notably, he spent over seven years as the President and Chief Scientific Officer of Medistem, where he developed and commercialized the Endometrial Regenerative Cell through various clinical trial phases, culminating in Medistem Inc.'s acquisition by Intrexon in a $26 million deal.
AI Analysis | Feedback
The key risks to Creative Medical Technology Holdings, Inc. (CELZ) include:
- Significant Cash Burn and Dependence on Future Financing: As a clinical-stage biotechnology company, Creative Medical Technology Holdings, Inc. operates with minimal revenue and incurs substantial research and development expenses, resulting in a considerable cash burn. The company's continued operations and advancement of its therapeutic pipeline are heavily reliant on its ability to secure additional financing in the future, which could lead to dilution for current shareholders.
- Clinical Development and Regulatory Approval Risks: The success of Creative Medical Technology Holdings, Inc. is contingent upon its ability to navigate the lengthy, costly, and uncertain process of clinical trials for its adult stem cell therapies. There is no assurance that these novel therapies will demonstrate sufficient safety and efficacy in larger studies or ultimately receive the necessary regulatory approvals from health authorities such as the FDA. Furthermore, the inherent complexities of stem cell treatments, including potential risks of contamination, immune reactions, or unforeseen cellular behavior, contribute to these significant clinical and regulatory hurdles.
- Intense Competition and Market Acceptance: Should Creative Medical Technology Holdings, Inc.'s therapies gain regulatory approval, they will enter highly competitive markets with existing treatments and other companies developing regenerative medicine solutions. The commercial success of the company's products will depend on various factors, including their differentiated efficacy, safety profile, pricing, and the ultimate acceptance and adoption by healthcare providers and patients in therapeutic areas such as urology, orthopedics, and neurology.
AI Analysis | Feedback
nullAI Analysis | Feedback
Creative Medical Technology Holdings, Inc. (CELZ) - Addressable Market Sizes for Main Products:
- CaverStem (Erectile Dysfunction Treatment): The global erectile dysfunction (ED) market is projected to reach USD 6.7 billion by 2034, growing from USD 3.8 billion in 2025, at a compound annual growth rate (CAGR) of 6.4%. The global erectile dysfunction drugs market was estimated at approximately USD 2.9 billion in 2024 and is expected to grow to USD 7 billion by 2034, with a CAGR of 9.2%. The North American erectile dysfunction drugs market accounted for 50.55% of the global revenue share in 2024.
- FemCelz (Female Genital Sensitivity and Dryness / Female Sexual Dysfunction Treatment): The global female sexual dysfunction treatment market was valued at USD 495.3 million in 2023 and is estimated to reach USD 1.1 billion by 2032, with a 10% CAGR. Another report valued the global market at USD 542.97 million in 2024 and expects it to grow to USD 1.63 billion by 2033, at a CAGR of 13%. North America holds the largest market share in the Female Sexual Dysfunction Treatment Market.
- StemSpine (Chronic Lower Back Pain Treatment): The global chronic lower back pain treatment market was valued at USD 2.84 billion in 2025 and is projected to grow to USD 6.95 billion by 2034, exhibiting a CAGR of 10.63%. The U.S. chronic lower back pain therapeutics market was approximately USD 4.218 billion in 2023. North America dominated the global chronic lower back pain treatment market with a 47.90% share in 2025. The total costs associated with chronic lower back pain in the U.S. are estimated to be between USD 100 billion and USD 200 billion annually.
- ImmCelz (Stroke Treatment): The global stroke treatment market size was estimated at USD 37.84 billion in 2025 and is expected to reach USD 70.04 billion by 2033, with a CAGR of 8.00%. The global stroke diagnostic and therapeutic market is calculated at USD 45.41 billion in 2026 and is expected to surpass USD 90.62 billion by 2035, growing at a CAGR of 7.98%. The U.S. stroke diagnostic and therapeutic market size was evaluated at USD 6.40 billion in 2025 and is predicted to be worth around USD 15.04 billion by 2035. North America held the largest share of the stroke diagnostic and therapeutic market, accounting for 26.82% in 2025. Creative Medical Technology also states that harmful immune responses, or autoimmunity, comprise a multibillion-dollar market.
- OvaStem (Female Infertility Treatment): The global female infertility market was estimated at USD 27.59 billion in 2023 and is projected to reach USD 41.41 billion by 2030, growing at a CAGR of 6%. The female infertility market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is expected to grow from USD 1.6 billion in 2023 to USD 2.3 billion in 2033. The global female infertility drugs market was valued at USD 4.69 billion in 2024 and is projected to grow to USD 7.11 billion by 2034, exhibiting a CAGR of 6.3%. North America accounted for 22.2% of the global female infertility market in 2023.
AI Analysis | Feedback
Creative Medical Technology Holdings, Inc. (CELZ) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends in the regenerative medicine sector:
- Advancement and Commercialization of Lead Clinical Programs: A primary driver for CELZ's future revenue is the successful progression and potential commercialization of its advanced clinical programs. Specifically, the CELZ-201-DDT (ADAPT Trial) targeting chronic lower back pain from degenerative disc disease, which addresses an estimated $11 billion annual market, received FDA Fast Track Designation in August 2025 with topline results anticipated in the first half of 2026. Additionally, the CELZ-201 (CREATE-1 Trial) for new-onset Type 1 Diabetes is focused on a global treatment market estimated at $35 billion annually. These programs, leveraging the AlloStem platform, are considered significant near-term catalysts for the company.
- Expansion and Potential Market Adoption of OvaStem for Female Infertility: The OvaStem program for treating female infertility and premature ovarian failure shows strong potential. Pilot study data demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies with no safety concerns. The company has filed for Orphan Drug Designation for Primary Ovarian Insufficiency (POI), and a presidential initiative to lower IVF costs could significantly increase market adoption for OvaStem as a novel alternative.
- Increased Efficiency and Broadening Applications of the ImmCelz Platform: The ImmCelz personalized immunotherapy platform is poised for growth due to significant advancements. The company achieved a 400% increase in clinical grade cell production yield at the same cost profile, which substantially reduces production costs and allows for accelerated clinical applications and potential collaborations. Furthermore, Creative Medical has strengthened its intellectual property with new patents expanding ImmCelz coverage to lucrative markets such as Type 1 Diabetes and Heart Failure.
- Strategic Partnerships and Licensing Agreements Driven by Robust Intellectual Property: Creative Medical Technology Holdings has a strong intellectual property portfolio with over 60 patents and pending applications across its various platforms, including AlloStem, ImmCelz, and iPScelz. This extensive patent portfolio forms a crucial foundation for potential strategic partnerships and licensing discussions, which can expand market reach and generate revenue through collaborations in the regenerative medicine space.
- Overall Growth in the Regenerative Medicine and Stem Cell Therapy Market: The broader market trends for stem cell therapy and manufacturing are highly favorable, providing a conducive environment for CELZ's specialized offerings. The global stem cell manufacturing market is estimated to reach $34.54 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.2% from 2025. Similarly, the global stem cell therapy market is projected to grow at a healthy rate of 20% by 2029, driven by increasing R&D, clinical trials, and demand for advanced regenerative therapies.
AI Analysis | Feedback
Share Repurchases
- An equity buyback of $2 million worth of shares was announced on June 13, likely in 2025.
- In 2020, Creative Medical Technology Holdings, Inc. made share repurchases amounting to $0.27 million.
Share Issuance
- The company issued $1.45 million in capital stock in 2021.
- The number of shares outstanding increased by 52.67% in one year, reaching 3.49 million shares.
- A 1:10 reverse stock split was executed on June 12, 2023.
Inbound Investments
- Agreements for the exercise of warrants generated $4.2 million in gross proceeds for the company around October/November 2025.
Capital Expenditures
- Available financial data indicates capital expenditures as "n/a" for the last 12 months.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CELZ.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.89 |
| Mkt Cap | 1.3 |
| Rev LTM | 491 |
| Op Inc LTM | 25 |
| FCF LTM | -15 |
| FCF 3Y Avg | -5 |
| CFO LTM | -8 |
| CFO 3Y Avg | 3 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.2% |
| Rev Chg 3Y Avg | 13.3% |
| Rev Chg Q | 4.8% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | 9.9% |
| Op Mgn 3Y Avg | 5.8% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | -1.8% |
| CFO/Rev 3Y Avg | 2.8% |
| FCF/Rev LTM | -4.3% |
| FCF/Rev 3Y Avg | -0.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.3 |
| P/S | 1.3 |
| P/EBIT | 2.2 |
| P/E | 3.5 |
| P/CFO | -5.5 |
| Total Yield | -4.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -3.1% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.5% |
| 3M Rtn | -13.3% |
| 6M Rtn | -33.1% |
| 12M Rtn | -31.2% |
| 3Y Rtn | 7.9% |
| 1M Excs Rtn | -8.5% |
| 3M Excs Rtn | -7.2% |
| 6M Excs Rtn | -28.2% |
| 12M Excs Rtn | -43.3% |
| 3Y Excs Rtn | -53.9% |
Price Behavior
Price Behavior
| Market Price | $1.97 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -64.8% | |
| 50 Days | 200 Days | |
| DMA Price | $1.92 | $2.67 |
| DMA Trend | down | down |
| Distance from DMA | 2.4% | -26.3% |
| 3M | 1YR | |
| Volatility | 71.8% | 101.4% |
| Downside Capture | 1.04 | 0.74 |
| Upside Capture | 195.13 | 71.60 |
| Correlation (SPY) | 26.0% | 16.3% |
CELZ Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.55 | 2.41 | 2.42 | 2.30 | 1.03 | 0.93 |
| Up Beta | 4.14 | 4.37 | 4.44 | 5.68 | 1.02 | 0.90 |
| Down Beta | 4.20 | 1.89 | 0.80 | 2.49 | 1.02 | 1.04 |
| Up Capture | 258% | 201% | 130% | 20% | 22% | 23% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 19 | 27 | 61 | 120 | 342 |
| Down Capture | 359% | 206% | 319% | 180% | 131% | 105% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 22 | 33 | 59 | 119 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -10.2% | 101.1% | 0.35 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 9.2% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 16.2% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 6.2% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 5.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 12.2% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -38.3% | 128.5% | 0.09 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 5.9% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 10.6% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 3.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 3.1% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 7.8% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 9.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CELZ | |
|---|---|---|---|---|
| CELZ | -12.1% | 6,837.8% | 0.44 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 2.3% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 1.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -1.7% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -4.2% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 0.7% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | -0.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/20/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.